Session Details

F001 Alopecia Areata: New Therapies

Fri, Mar 19, 9:00 AM - 11:00 AM
2 CME Available Forum

DESCRIPTION

With the current interest in hair loss conditions being on the rise, it is important to understand alopecia areata as it is the most common cause of immune- mediated alopecia, affecting 2% of the USA population. The intricate pathology, patients demographics and comorbidities, and the new therapeutic options will be discussed. The team of speakers have been leaders in developing alopecia areata severity scale and therapeutic guidelines.

LEARNING OBJECTIVES

1.

Compare and analyze novel therapies for alopecia areata

2.

Identify patients who are eligible for novel medications considering their comorbidities

3.

Describe therapeutic guidelines for alopecia areata, including dosing, duration of treatment and clinical prognosis

DIRECTOR

Natasha Atanaskova Mesinkovska, PhD, MD, FAAD

Natasha Atanaskova Mesinkovska, PhD, MD, FAAD

DISCLOSURES

Natasha Atanaskova Mesinkovska, PhD, MD, FAAD

AbbVie – Investigator(No Compensation Received); Arcutis, Inc. – Investigator(No Compensation Received); Arena Pharmaceuticals – Advisory Board(Honoraria), Investigator(No Compensation Received); Concert Pharmaceuticals – Advisory Board(Honoraria); Eli Lilly – Speaker(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Investigator(No Compensation Received); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Investigator(No Compensation Received); Merz Aesthetics – Investigator(Grants/Research Funding); Nutrafol – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);